NCT02862535 - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

October 25, 2019

Study Completion Date

October 25, 2019

Conditions

Gastric Adenocarcinoma

Interventions

DRUG

Andecaliximab

Administered via intravenous (IV) infusion (approximately 30 minutes)

DRUG

S-1

Administered orally

DRUG

Cisplatin

Administered via IV infusion on Day 8 of every 5 weeks

DRUG

Oxaliplatin

Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle

DRUG

Nivolumab

Administered via IV infusion (approximately 60 minutes) every 2 weeks

Trial Locations (3)

Nagoya

Osaka

Tokyo